Stemedica   Report issue

For profit Phase 2
Founded: San Diego CA United States (2005)

Organization Overview

First Clinical Trial
2011
NCT01297413
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Clinica Santa Clarita, Mexico | External | Stemedica Cell Technologies | Stemedica Cell Technologies, Inc. | Stemedica International SA

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Cerebral Infarction (Phase 2)

Dementia (Phase 2)

Heart Failure (Phase 2)

Infarction (Phase 2)

Ischemia (Phase 2)

Myocardial Infarction (Phase 2)

Osteoarthritis (Phase 1)

Osteoarthritis, Knee (Phase 1)

Skin Diseases (Phase 2)

ST Elevation Myocardial Infarction (Phase 2)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 4